Electric Motor Technology Company YASA Acquired by Mercedes-Benz
22.7.2021 15:00:00 EEST | Business Wire | Press release
Mercedes-Benz today announced the acquisition of YASA, a pioneer in next-generation electric drive technology. Under the terms of the acquisition, YASA will operate as a wholly owned subsidiary of Mercedes-Benz, developing ultra high-performance e-motors, while retaining its own brand, team, facilities and continuing to supply existing automotive supercar customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005414/en/
YASA’s axial-flux electric motor - a step-change from legacy radial motors, giving end customers greater range and unsurpassed driving experiences. (Photo: Business Wire)
Electric motors are a fast developing area of technology where innovation and expertise drive performance and differentiation. YASA will help to develop pioneering best-in-class electric drive innovations to give Mercedes-Benz exceptional performance in a new electric era.
Founded in 2009, YASA’s proprietary axial-flux electric motor is a step-change from the legacy radial electric motor technology. YASA’s patented e-motors deliver the greatest efficiencies and highest power densities in class for the smallest possible size and weight, giving end customers unsurpassed driving experiences.
Following the acquisition, YASA and its 250 employees will continue to operate from its headquarters and production facility in Oxford, UK. YASA will provide electric motors for Mercedes-Benz’s AMG.EA electric-only platform, while also acting as an innovation partner pioneering new electric drive technology for the Group.
Chris Harris, CEO, YASA said, “Working with Mercedes-Benz since 2019, it was always clear that we shared the same commitment to engineering excellence, innovation and reshaping mobility for the electric age. This acquisition is tremendously exciting because it gives YASA technology the global scale and reach of Mercedes-Benz. Together, we have the opportunity to make YASA the premier mark of excellence in electric motor technology, accelerating the adoption of electric vehicles and resetting the bar for electric driving experiences.”
YASA’s expertise and resources will be focused on delivering world-beating electric drive technologies for AMG-Mercedes’ electric-only platform.
Philipp Schiemer, CEO of Mercedes-AMG and Head of the Top End Vehicle Group, said, “We warmly welcome YASA to Mercedes-Benz. YASA’s impressive axial-flux technology allows future fully electric Mercedes-AMG performance cars to stay a step ahead of the competition. Thanks to electric motors with higher power density and continuous torque delivery we will redefine the future of driving performance.”
<ends>
EDITOR’S NOTES
YASA http://www.yasa.com/
YASA, part of Mercedes-Benz AG, is a pioneer in next-generation electric drive technology. YASA’s unique axial-flux electric motor technology offers the greatest efficiencies and highest power densities in class for the smallest size and weight. YASA is based in Oxford and Welshpool.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005414/en/
Contact information
For media enquiries, images and interviews, please contact:
Tamara Sword on tam@thoughtldr.com
+44 (0)203 417 0717 // +44 (0)7906 638351
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom